循环游离DNA中雄激素受体增益及外泌体AR-V7预测CRPC患者对阿比特龙和恩扎卢胺的临床结局
结果显示基线AR增益和AR-V7阳性均与更短的无进展生存期(PFS)和总生存期(OS)显著相关,两者联合检测可强预测对AR信号抑制剂的耐药。
要点
- 基线AR-V7阳性患者中位PFS为5.4个月,AR-V7阴性为24.3个月(p<0.0001)。
- 基线AR增益患者中位PFS为4.8个月,AR正常为24.3个月(p<0.0001)。
- AR增益/AR-V7联合检测可强预测对阿比特龙或恩扎卢胺的耐药。
核心结论
- cfDNA和外泌体RNA均是检测AR变异的可靠来源,两者联合液体活检可预测mCRPC患者对AR信号抑制剂的耐药。
研究设计与样本
- 通过数字液滴PCR分别检测cfDNA中的AR增益和外泌体RNA中的AR-V7。
主要发现
- AR-V7阴性vs阳性患者的中位PFS为24.3 vs 5.4个月(p<0.0001),中位OS为未达到 vs 16.2个月(p=0.0001)。
- AR正常vs AR增益患者的中位PFS为24.3 vs 4.8个月(p<0.0001),中位OS为未达到 vs 8.17个月(p<0.0001)。
- AR-V7与AR增益存在显著相关性(r=0.28;p=0.01)。
- AR增益/AR-V7联合分析显示,无任何AR畸变患者vs有任一畸变患者的中位PFS为28 vs 3.8个月,中位OS为未达到 vs 6.1个月(p<0.0001)。
关键数值与推荐
- 基线AR-V7阳性率35.7%,AR增益率14.3%。
- AR-V7阳性与更短PFS(5.4 vs 24.3个月)和OS(16.2个月 vs 未达到)显著相关。
- AR增益与更短PFS(4.8 vs 24.3个月)和OS(8.17个月 vs 未达到)显著相关。
- AR增益与AR-V7显著相关(r=0.28;p=0.01)。
- 联合检测中,有AR畸变患者PFS为3.8个月,无畸变为28个月;OS为6.1个月 vs 未达到(p<0.0001)。
临床怎么用
- 在mCRPC患者启动阿比特龙或恩扎卢胺一线治疗前,可考虑通过液体活检同时检测cfDNA中的AR增益和外泌体RNA中的AR-V7。
- AR增益或AR-V7阳性提示对AR信号抑制剂原发耐药风险高,可辅助治疗决策。
- 联合检测较单一标志物能更强预测治疗结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Androgen receptor (AR) signaling inhibitors represent the standard treatment in metastatic castration resistance prostate cancer (mCRPC) patients. However, some patients display a primary resistance, and several studies investigated the role of the AR as a predictive biomarker of response to treatment. This study is aimed to evaluate the role of AR in liquid biopsy to predict clinical outcome to AR signaling inhibitors in mCRPC patients. METHODS: Six milliliters of plasma samples were collected before first-line treatment with abiraterone or enzalutamide. Circulating free DNA (cfDNA) and exosome-RNA were isolated for analysis of AR gain and AR splice variant 7 (AR-V7), respectively, by digital droplet PCR. RESULTS: Eighty-four mCRPC patients received abiraterone (n = 40) or enzalutamide (n = 44) as first-line therapy. Twelve patients (14.3%) presented AR gain and 30 (35.7%) AR-V7+ at baseline. Median progression-free survival (PFS) and overall survival (OS) were significantly longer in AR-V7- vs AR-V7+ patients (24.3 vs 5.4 months, p < 0.0001; not reached vs 16.2 months, p = 0.0001, respectively). Patients carrying the AR gain had a median PFS of 4.8 vs 24.3 months for AR normal patients (p < 0.0001). Median OS was significantly longer in AR normal vs patients with AR gain (not reached vs 8.17 months, p < 0.0001). A significant correlation between AR-V7 and AR gain was observed (r = 0.28; p = 0.01). The AR gain/AR-V7 combined analysis confirmed a strong predictive effect for biomarkers combination vs patients without any AR aberration (PFS 3.8 vs 28 month, respectively; OS 6.1 vs not reached, respectively; p < 0.0001). CONCLUSIONS: The present study demonstrates that cfDNA and exosome-RNA are both a reliable source of AR variants and their combined detection in liquid biopsy predicts resistance to AR signaling inhibitors.
引用
- Del Re M, Conteduca V, Crucitta S, et al. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. Prostate Cancer Prostatic Dis. 2021. PMID: 33500577. doi:10.1038/s41391-020-00309-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。